Cerenome
a regenerative-medicine company, based in San Diego
Cerenome, Inc. (formerly Plus Therapeutics, Inc.) is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system (CNS) cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™ (rhenium Re-186 obisbemeda), is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Cerenome also commercialized a molecular diagnostic service, CNSide®.
Company history
Cerenome, Inc. (Plus Therapeutics, Inc. until August 3, 2026), was formerly known as Cytori Therapeutics, Inc. In 2017, Cytori Therapeutics announced that it had acquired a nanomedicine platform. In 2019, Cytori Therapeutics announced that it had divested its autologous cell therapy assets to Lorem Vascular of Australia and Seijiro Shirahama of Japan. In 2019, Cytori Therapeutics announced that it had changed its focus and name to Plus Therapeutics.
“Cerenome” enters the record as a regenerative-medicine company, based in San Diego. Crown Archives preserves that source wording while asking what Cerenome, regenerative-medicine and company can confirm, complicate or overturn.
Why this record matters
“Cerenome” is worth following because a concise public description often conceals a longer documentary argument. Here, Cerenome, regenerative-medicine and company provides the most credible route into that argument.
Datasets, specimens, observations and peer-reviewed methods provide the appropriate test for the technical claims summarized here. The source revision retrieved here is dated Aug 26, 2026. The linked authority identifier is Q5201379. VIAF identifies the subject as 129337658. The Library of Congress control number is no2001094350. 1 of 4 selected statements include explicit references; 1 carry qualifiers and 0 use preferred rank. The first chronological checks are 2026, 2017 and 2019.
Scientific names, classifications and consensus can change while older terminology persists in catalogues and historical literature. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Cerenome”, its source revision and the description used here.
- Expand the search: follow Cerenome primary sources, Cerenome archive and Cerenome research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Cerenome”?
- Has classification or technical consensus changed since the cited source?
- Which observation, specimen, dataset or publication supports the account?
Search terms from this dossier
This entry incorporates text from “Cerenome” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.